✦ LIBER ✦

An open-label evaluation of the tolerability and safety of Stalevo® (carbidopa, levodopa and entacapone) in Parkinson’s disease patients experiencing wearing-off

✍ Scribed by W. Koller; M. Guarnieri; J. Hubble; A. L. Rabinowicz; D. Silver

Publisher: Springer
Year: 2004
Tongue: English
Weight: 80 KB
Volume: 112
Category: Article
ISSN: 1435-1463
DOI: 10.1007/s00702-004-0184-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Direct switch from levodopa/benserazide

Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson’s disease patients with wearing-off: efficacy, safety and feasibility—an open-label, 6-week study

✍ Karla Eggert; Örjan Skogar; Khaled Amar; Liisa Luotonen; Mikko Kuoppamäki; Mika 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 335 KB

Use of the new levodopa agent Stalevo (l

Use of the new levodopa agent Stalevo (levodopa/carbidopa/entacapone) in the treatment of Parkinson's disease in out-patient clinical practice (the START-M open trial)

✍ A. N. Boiko; T. T. Batysheva; N. G. Minaeva; L. A. Babina; T. V. Vdovichenko; E. 📂 Article 📅 2008 🏛 Springer US 🌐 English ⚖ 200 KB

Efficacy and tolerability of entacapone

Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study

✍ G. Fénelon; S. Giménez-Roldán; J. L. Montastruc; F. Bermejo; F. Durif; I. Bourde 📂 Article 📅 2003 🏛 Springer 🌐 English ⚖ 121 KB

Combining entacapone with levodopa/DDCI

Combining entacapone with levodopa/DDCI improves clinical status and quality of life in Parkinson’s Disease (PD) patients experiencing wearing-off, regardless of the dosing frequency: results of a large multicentre open-label study

✍ M. Onofrj; A. Thomas; F. Vingerhoets; W. Martin; S. Giménez-Roldán; J.-P. Azulay 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 292 KB

Open-label flexible-dose pilot study to

Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease

✍ Joseph H. Friedman; Robert M. Berman; Christopher G. Goetz; Stewart A. Factor; W 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB 👁 2 views

## Abstract Psychosis affects at least 5% to 8% of medication‐treated patients with idiopathic Parkinson's disease (PD). Treatment options include reducing medications used for the treatment of PD‐related motor symptoms or introducing an atypical antipsychotic drug. Only clozapine has been demonstr

Open label, multicenter, 28-week extensi

Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer’s disease

✍ Brian R. Ott; Lesley M. Blake; Ethel Kagan; Malca Resnick; for the Memantine MEM 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 142 KB